DK2185698T3 - Kinaseinhibitorer og anvendelser deraf - Google Patents
Kinaseinhibitorer og anvendelser deraf Download PDFInfo
- Publication number
- DK2185698T3 DK2185698T3 DK08797416.8T DK08797416T DK2185698T3 DK 2185698 T3 DK2185698 T3 DK 2185698T3 DK 08797416 T DK08797416 T DK 08797416T DK 2185698 T3 DK2185698 T3 DK 2185698T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase
- peptide
- seq
- inhibiting
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Claims (13)
1. Kinaseinhiberende sammensætning, der omfatter et kinaseinhiberende peptid til inhibering af vækst af et neoplasma, hvor det kinaseinhiberende peptid er et peptid med en aminosyresekvens valgt blandt gruppen bestående af HRRIKAWLKKIKALARQLGVAA [SEQ ID NO: 166]; WLRRIKAWLRRIKALARQLGVAA [SEQ ID NO: 113]; WLRRIKAWLRRALARQLGVA [SEQ ID NO: 177]; KAFAKLAARLYRKALARQLGVAA [SEQ ID NO: 173]; FAKLAARLYRKALARQLGVAA [SEQ ID NO: 163]; YARAAARQARAKALARQLGVAA [SEQ ID NO: 106]; YARAAARQARAKALNRQLGVA [SEQ ID NO: 28]; YARAAARQARAKALNRQLAVAA [SEQ ID NO: 100]; og YARAAARQARAKALNRQLAVA [SEQ ID NO: 64],
2. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens HRRIKAWLKKIKALARQLGVAA [SEQ ID NO: 166],
3. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens WLRRIKAWLRRIKALARQLGVAA [SEQ ID NO: 113],
4. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens WLRRIKAWLRRALARQLGVA [SEQ ID NO: 177],
5. Kinaseinhiberende sammensætning ifølge krav 1 til anvendelse i en fremgangsmåde til behandling af et neoplasma valgt blandt gruppen bestående af et papillom, et adenom, et hydatidiformmodermærke, et fibrom, et chondrom, et osteom, et leiomyom, et rhabdomyom, et lipom, et hemangiom, et lymphangiom, et polycythaemia vera, en infektiøs mononucleose, et "godartet giiom”, et menin-giom, et ganglioneurom, et neurilemmom, et neurofibrom, et pigmenteret næves (modermærke), et pheochromocytom, en carcinoid tumor, et te ratom, et carei-nom, et adenocarcinom, et basaiceiiecarcinom, et choriocarcinom, et fibrosar-kom, et cbondrosarkom, et osteosarkom, et leiomyosarkom, et rhabdomyosar-kom, et liposarkom, et hemangiosarkom, et lymphangiosarkom, en myeiocytisk leukemi, en erythrocytisk leukemi, en lymphocytisk leukemi, et multipelt myelom, en monocytisk leukemi, et Ewing sarkom, et ondartet non-Hodgkin iymfom, et meduliobiastom, oligodendrogliom, et neurilemmaisarkom, ondartet melanom, thymon, en gliobiastom multiforme, et astrocytom, et ependymom, et meningeal-sarkom, et neuroblastom (schwannom), et neurofibrosarkom, et ondartet pheochromocytom, et retinoblastom, en carcinoid tumor, en nephroblastom (Wilms tumor), et teratocarcinom og et embryonaicarcinom med choriocarcinom.
8. Anvendelse af den kinaseinhiberende sammensætning ifølge krav 1 i fremstillingen af et medikament til behandling af et neoplasma valgt blandt gruppen bestående af et papillom, et adenom, et hydatidiformmodermærke, et fibrom, et chondrom, et osteom, et leiomyom, et rhabdomyom, et lipom, et hemangiom, et lymphangiom, et polycythaemia vera, en infektiøs mononucleose, et "godartet” giiom, et meningiom, et ganglioneurom, et neurilemmom, et neurofibrom, et pigmenteret nævus (modermærke), et pheochromocytom, en carcinoid tumor, et te ratom, et card nom, et adenocarcinom, et basaiceiiecarcinom, et choriocarci-nom, et fibrosarkom, et chondrosarkom, et osteosarkom, et leiomyosarkom, et rhabdomyosarkom, et liposarkom, et hemangiosarkom, et lymphangiosarkom, en myeiocytisk leukemi, en erythrocytisk leukemi, en lymphocytisk leukemi, et multipelt myelom, en monocytisk leukemi, et Ewing sarkom, et ondartet non-Hodgkin Iymfom, et meduliobiastom, oligodendrogliom, et neurilemmaisarkom, ondartet melanom, thymon, en gliobiastom multiforme, et astrocytom, et ependymom, et meningeaisarkom, et neuroblastom (schwannom), et neurofibrosarkom, et ondartet pheochromocytom, et retinoblastom, en carcinoid tumor, en nephroblastom (Wilms tumor), et teratocarcinom og et embryonaicarcinom med choriocarcinom.
7. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhibe-rende peptid er en cyclinafhængig kinaseinhibitor.
8. Kinaseinhiberende sammensætning ifølge krav 1, hvor sammensætningen inducerer programmeret celledød af mindst en celle i en cellepopulation.
9. Kinaseinhiberende sammensætning ifølge krav 1, hvor sammensætningen inhiberer hyperplasi af mindst en hyperplastisk celle i en cellepopulation.
10. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens KAFAKLAARLYRKALARQLGVAA [SEQ ID NO: 173],
11. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens FAKLAARLYRKALARQLGVAA [SEQ ID NO: 163],
12. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALARQLGVAA [SEQ ID NO: 106],
13. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLGVA [SEQ ID NO: 28].
14. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLAVAA [SEQ ID NO: 100],
15. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhibe-rende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLAVA [SEQ ID NO: 64],
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96394107P | 2007-08-07 | 2007-08-07 | |
US99497007P | 2007-09-24 | 2007-09-24 | |
PCT/US2008/072525 WO2009021137A2 (en) | 2007-08-07 | 2008-08-07 | Kinase inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2185698T3 true DK2185698T3 (da) | 2015-07-27 |
Family
ID=40342047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08797416.8T DK2185698T3 (da) | 2007-08-07 | 2008-08-07 | Kinaseinhibitorer og anvendelser deraf |
Country Status (7)
Country | Link |
---|---|
US (2) | US8741849B2 (da) |
EP (1) | EP2185698B1 (da) |
JP (1) | JP5703466B2 (da) |
DK (1) | DK2185698T3 (da) |
ES (1) | ES2547229T3 (da) |
HK (1) | HK1144306A1 (da) |
WO (1) | WO2009021137A2 (da) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080293640A1 (en) * | 2007-01-10 | 2008-11-27 | Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of | Polypeptide inhibitors of HSP27 kinase and uses therefor |
ES2476842T3 (es) * | 2007-01-10 | 2014-07-15 | Purdue Research Foundation | Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos |
WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
KR20170001756A (ko) * | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
CA2744104C (en) * | 2008-12-10 | 2017-07-18 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
WO2011017132A2 (en) * | 2009-07-27 | 2011-02-10 | Purdue Research, Foundation | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
US8530429B2 (en) * | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
MX365251B (es) | 2010-05-20 | 2019-05-28 | Array Biopharma Inc | Compuestos macrocíclicos como inhibidores de trk cinasa. |
US20130115256A1 (en) * | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
MX359516B (es) * | 2011-04-12 | 2018-10-01 | Moerae Matrix Inc | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
CN102949722A (zh) * | 2011-08-26 | 2013-03-06 | 中国医学科学院放射医学研究所 | 基于p38抑制剂和细胞生长因子的新颖药物组合物 |
CA2853722A1 (en) | 2011-10-27 | 2013-05-02 | Mayo Foundation For Medical Education And Research | Inhibiting g protein coupled receptor 6 kinase polypeptides |
EP2773777B1 (en) * | 2011-10-31 | 2020-05-13 | University of Utah Research Foundation | Genetic alterations in glioblastoma |
US9452218B2 (en) | 2012-03-09 | 2016-09-27 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
US20140072613A1 (en) * | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
WO2014160364A1 (en) * | 2013-03-13 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
US10835549B2 (en) | 2013-04-11 | 2020-11-17 | Vanderbilt University | Polyplexes |
GB201314610D0 (en) * | 2013-08-15 | 2013-10-02 | Blueberry Therapeutics Ltd | Compounds and their uses |
WO2015057461A2 (en) | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use |
CN103739678B (zh) * | 2013-12-31 | 2015-09-02 | 刘培臣 | 抑制粘附斑激酶多肽及其应用 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US9902739B2 (en) | 2014-04-21 | 2018-02-27 | Mayo Foundation For Medical Education And Research | Small molecule inhibitors of G protein coupled receptor 6 kinases polypeptides |
JP6768639B2 (ja) | 2014-05-23 | 2020-10-21 | セルデックス セラピューティクス,インコーポレーテッド | 好酸球又はマスト細胞関連障害の治療 |
US9730938B2 (en) | 2014-08-08 | 2017-08-15 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
US10512651B2 (en) * | 2014-08-25 | 2019-12-24 | Stc.Unm | Inhibition of MK2 in the treatment of cancer |
SG11201703939XA (en) | 2014-11-17 | 2017-06-29 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
JP2018502860A (ja) | 2015-01-08 | 2018-02-01 | モイライ マトリックス インコーポレイテッド | Mk2阻害ペプチド製剤 |
MX2017011633A (es) * | 2015-03-12 | 2017-11-02 | Moerae Matrix Inc | Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. |
PL3322706T3 (pl) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret |
EP3419980A4 (en) | 2016-02-26 | 2019-07-03 | The Board of Trustees of the Leland Stanford Junior University | INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
WO2019218016A1 (en) | 2018-05-15 | 2019-11-21 | Interk Peptide Therapeutics Limited | Peptide activating agent |
EP3794015A4 (en) * | 2018-05-15 | 2022-03-30 | InterK Peptide Therapeutics Limited | ACTIVATING AGENTS |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
CA3126143A1 (en) * | 2019-01-11 | 2020-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Pi4-kinase inhibitors with anti-cancer activity |
WO2021097407A2 (en) * | 2019-11-15 | 2021-05-20 | Regents Of The University Of Colorado, A Body Corporate | Novel peptide compositions and methods of treating neurological injury |
CN114605497B (zh) * | 2021-02-10 | 2023-04-28 | 北京欣安诚科技有限公司 | 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 |
CN115976033A (zh) * | 2022-12-14 | 2023-04-18 | 西南大学 | 瓜实蝇tssk1和tssk3基因及其应用 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
FI79651C (fi) | 1982-10-08 | 1990-02-12 | Glaxo Group Ltd | Doseringsanordning foer medicin. |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
US4811731A (en) | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
US5175144A (en) | 1988-11-29 | 1992-12-29 | The Johns Hopkins University | Method of retarding the progression of chronic renal failure |
JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
CA2080224A1 (en) | 1990-04-18 | 1991-10-19 | Jindrich Kopecek | Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling |
WO1993022443A1 (en) | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
DE69425903T2 (de) | 1993-12-09 | 2001-02-15 | Thomas Jefferson University Ph | Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen |
CA2314267A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
US7041814B1 (en) | 1998-02-18 | 2006-05-09 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics |
JP2002510336A (ja) * | 1998-04-11 | 2002-04-02 | エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ | 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法 |
US7601685B2 (en) | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
AU2001281304B2 (en) | 2000-08-15 | 2006-05-25 | Surmodics, Inc. | Medicament incorporation matrix |
US7858094B2 (en) | 2000-12-08 | 2010-12-28 | Geneprint Corporation | TREM-1 splice variant for use in modifying immune responses |
JP4115838B2 (ja) | 2001-01-18 | 2008-07-09 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | δPKCの活性化および阻害のためのペプチド |
DE10118774A1 (de) | 2001-04-17 | 2002-10-31 | Jerini Ag | Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
DK1523323T3 (da) | 2001-08-23 | 2013-10-28 | Univ Arizona | Reagenser og fremgangsmåder til behandlinger i den glatte muskulatur |
US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
WO2003072801A2 (en) * | 2002-02-21 | 2003-09-04 | The Rockefeller University | Compositions and method for regulation of calcium-dependent signalling in brain |
US20040005686A1 (en) | 2002-03-07 | 2004-01-08 | Pharmacia Corporation | Crystalline structure of human MAPKAP kinase-2 |
US20070026518A1 (en) | 2005-03-29 | 2007-02-01 | The Regents Of The University Of California | Controlling stem cell destiny with tunable matrices |
WO2003084481A2 (en) | 2002-04-01 | 2003-10-16 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Biological affinity based delivery systems |
CN1735687A (zh) | 2002-08-02 | 2006-02-15 | 惠氏公司 | Mk2相互作用蛋白 |
AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
DE602004001509T2 (de) | 2003-02-21 | 2007-02-15 | Arizona Board Of Regents, Tempe | Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung |
IL156429A0 (en) | 2003-06-12 | 2004-01-04 | Peptor Ltd | Cell permeable conjugates of peptides for inhibition of protein kinases |
CA2542639A1 (en) | 2003-10-17 | 2005-04-28 | Arizona Board Of Regents | Novel heat shock protein 20-related polypeptides and uses therefor |
WO2005114221A2 (en) | 2004-05-21 | 2005-12-01 | The Institute For Systems Biology | Compositions and methods for quantification of serum glycoproteins |
WO2006132647A2 (en) | 2004-07-23 | 2006-12-14 | The Trustees Of The University Of Pennsylvania | Antimicrobial copolymers and uses thereof |
EP1824498A4 (en) * | 2004-11-12 | 2009-06-24 | Massachusetts Inst Technology | METHODS AND COMPOSITIONS FOR TREATING CELLULAR PROLIFERATIVE DISEASES |
EP1824336A4 (en) | 2004-12-02 | 2009-10-14 | Univ North Carolina | INHIBITION OF PHOSPHORYLATION HSP27 TO TREAT VESICATION DISORDERS |
JP5116663B2 (ja) | 2005-04-15 | 2013-01-09 | アリゾナ バイオメディカル リサーチ コミッション | 転移癌の処置のための治療用ペプチド |
ES2628031T3 (es) | 2005-10-26 | 2017-08-01 | Genesis Technologies Limited | Matrices de regeneración tisular acelulares bioabsorbibles producidas mediante incubación de productos sanguíneos acelulares |
JP2009513158A (ja) | 2005-11-01 | 2009-04-02 | アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティ | 新規タンパク質伝達ドメインおよびその使用 |
WO2007062060A2 (en) | 2005-11-22 | 2007-05-31 | Ted Reid | Methods and compositions using substance p to promote wound healing |
EP2051727A4 (en) | 2006-07-12 | 2012-03-14 | Univ Arizona | METHOD FOR THE TREATMENT OF FIBROTIC DISEASES AND KELOIDS |
US20080293640A1 (en) * | 2007-01-10 | 2008-11-27 | Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of | Polypeptide inhibitors of HSP27 kinase and uses therefor |
ES2476842T3 (es) | 2007-01-10 | 2014-07-15 | Purdue Research Foundation | Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos |
WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
US20090269406A1 (en) | 2008-04-02 | 2009-10-29 | Alyssa Panitch | Therapeutic uses of biocompatible biogel compositions |
KR20170001756A (ko) | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
CA2744104C (en) | 2008-12-10 | 2017-07-18 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
WO2011017132A2 (en) | 2009-07-27 | 2011-02-10 | Purdue Research, Foundation | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US20130115256A1 (en) | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
MX359516B (es) | 2011-04-12 | 2018-10-01 | Moerae Matrix Inc | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. |
-
2008
- 2008-08-07 WO PCT/US2008/072525 patent/WO2009021137A2/en active Application Filing
- 2008-08-07 US US12/188,109 patent/US8741849B2/en not_active Expired - Fee Related
- 2008-08-07 JP JP2010520314A patent/JP5703466B2/ja not_active Expired - Fee Related
- 2008-08-07 EP EP20080797416 patent/EP2185698B1/en not_active Not-in-force
- 2008-08-07 ES ES08797416.8T patent/ES2547229T3/es active Active
- 2008-08-07 DK DK08797416.8T patent/DK2185698T3/da active
-
2010
- 2010-11-18 HK HK10110773.0A patent/HK1144306A1/zh not_active IP Right Cessation
-
2014
- 2014-04-22 US US14/258,418 patent/US9447158B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2185698A2 (en) | 2010-05-19 |
EP2185698A4 (en) | 2012-03-28 |
JP5703466B2 (ja) | 2015-04-22 |
JP2010535508A (ja) | 2010-11-25 |
US20140342993A1 (en) | 2014-11-20 |
ES2547229T3 (es) | 2015-10-02 |
WO2009021137A2 (en) | 2009-02-12 |
US20130184221A9 (en) | 2013-07-18 |
EP2185698B1 (en) | 2015-04-22 |
HK1144306A1 (zh) | 2011-02-11 |
US20090149389A1 (en) | 2009-06-11 |
WO2009021137A3 (en) | 2009-07-09 |
US9447158B2 (en) | 2016-09-20 |
US8741849B2 (en) | 2014-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2185698T3 (da) | Kinaseinhibitorer og anvendelser deraf | |
US9327008B2 (en) | Cell-permeant peptide-based inhibitor of kinases | |
US9999655B2 (en) | Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
WO2011160016A2 (en) | E3 binding pockets and identification and use of e3 ligase inhibitors | |
AU2007233784A1 (en) | Use of a kinase inhibitor for the treatment of particular resistant tumors | |
Goel et al. | The unique N‐terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1 | |
Kumar et al. | Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling | |
US20030077262A1 (en) | Methods and compositions for modulating apoptosis | |
ES2313029T3 (es) | Metodo para evaluar la actividad de fosforilacion de lkb1. | |
CN107353344B (zh) | 一种能特异地杀死活化b细胞型弥漫性大b细胞淋巴瘤的多肽及其应用 | |
AU2013202108B2 (en) | Cell-permeant peptide-based inhibitor of kinases | |
US20190022176A1 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
AU2016201861B2 (en) | Cell-permeant peptide-based inhibitor of kinases | |
US6641994B2 (en) | Methods of identifying anti-viral agents | |
WO2006001275A1 (ja) | グリコーゲン合成酵素を直接活性化する化合物をスクリーニングする方法 | |
JP4273232B2 (ja) | サイクリン依存性キナーゼ5(Cdk5)特異的ペプチド性阻害剤 | |
US20240083948A1 (en) | Modified peptides and associated methods of use | |
WO2022217068A1 (en) | Methods of treatment for leukemia | |
US20140030726A1 (en) | Methods for identifying modulators of murine double minute 2 | |
CN117957239A (en) | Cancer therapeutic agent | |
US20040121463A1 (en) | Methods and compositions for modulating apoptosis | |
Pan | Bruton |